BioSpace News Archive

PetMed Express, Inc. announced its financial results for its fourth quarter and fiscal year ended March 31, 2020.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release first quarter 2020 financial results after market close on Monday, May 11, 2020. Further, Catalyst management will host an investment-community conference cal

KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational product candidate, KP415

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 8, 2020 at 10:00 a.m. EDT to report its first quarter 2020 financial results and provide an update on its b

The Osteoarthritis Action Alliance, in partnership with the Centers for Disease Control and Prevention and the Arthritis Foundation, have updated the National Public Health Agenda for Osteoarthritis for 2020.

Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus.

Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has invested in Altoida, Inc. following the company’s $6.3 million Series A round in 2019..

As the current COVID-19 health crisis demonstrates, medical laboratories and the pathologists who oversee them to develop and conduct tests are relied upon to steer many of the health care decisions for the ultimate wellbeing of patients everywhere.

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced the appointments of Jeffrey A. Chodakewitz, M.D., and Gary Ginsberg to its Board of Directors.

Ribon Therapeutics announced that Victoria Richon, Ph.D., President and CEO, will present at two upcoming virtual healthcare conferences. Presentations will consist of a panel discussion and a corporate overview..